Filter posts

Sizing up the NBI in 2011

How did the Nasdaq Biotechnology Index (NBI) perform in 2011 relative to other sectors? Second …

IPO Update - Jan 2012

2011 ended quietly for the US biotech IPO market. It has now been almost two …

Where's the Deal?

With only two weeks to go in 2011 it is looking like a five year …

Just how big is $11 Billion? GILD Acquires VRUS

Seeing the markets open down 2% or more on a Monday morning feels like “business …

Public Exits and Virtual Biotechs - Dreams or Reality?

Here at the 10th Annual BIO Investor Forum, investors and CEOs are debating “all the …

Perspective on Market Valuation for Biotech Drug Developers

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% …

Biotech IPO Window - Still Ajar?

IPO plans for Quark Pharmaceuticals were officially put on hold last week as markets continue …

BioWorld previews BIO India: India Emerges as Global Player via Multinational Partnering

BioWorld’s Tom Wall interviewed BIO’s Alan Eisenberg (subscription required) on what attendees can expect at …

The Burrill Report: Pushing Policies in a Changed Washington

The Burrill Report’s Daniel Levine talks to BIO’s Alan Eisenberg regarding recent fluctuations in the …

2011 BIO International Convention: The evolution of one-on-one partnering

From the beginning, networking has been a central focus at BIO’s events.  Our members attend …